+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Stargardt Disease Pipeline Analysis and Outlook, 2019

  • ID: 4772538
  • Report
  • May 2019
  • Region: Global
  • 81 pages
  • VPA Research
until Oct 31st 2021


  • Acucela Inc
  • Biophytis SA
  • Generation Bio Corp
  • Katairo GmbH
  • Ophthotech Corporation
  • ReVision Therapeutics
Stargardt Disease pipeline

Stargardt Disease pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Stargardt Disease R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Stargardt Disease report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Stargardt Disease as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Stargardt Disease with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Stargardt Disease pipeline Profiled in detail

Key players actively participating in Stargardt Disease pipeline are profiled along with their R&D progress in Stargardt Disease treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Stargardt Disease pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Stargardt Disease treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Stargardt Disease pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Stargardt Disease pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Stargardt Disease pipeline study
  • All recent news and developments related to Stargardt Disease drugs are provided
Note: Product cover images may vary from those shown


  • Acucela Inc
  • Biophytis SA
  • Generation Bio Corp
  • Katairo GmbH
  • Ophthotech Corporation
  • ReVision Therapeutics
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Stargardt Disease Disease Overview

3. Stargardt Disease Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Stargardt Disease Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Stargardt Disease Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Stargardt Disease companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Stargardt Disease Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Acucela Inc
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biophytis SA
  • Cardax Pharmaceuticals
  • Generation Bio Corp
  • Ichor Therapeutics Inc
  • Katairo GmbH
  • Lin Bioscience Inc
  • Nightstar Therapeutics PLC
  • Ophthotech Corporation
  • ProQR Therapeutics NV
  • ReVision Therapeutics
  • Sanofi
  • Vision Medicines Inc
  • Vitrisa Therapeutics
  • WAVE Life Sciences Ltd
Note: Product cover images may vary from those shown